Satraplatin
Star0
Identification
- Generic Name
- Satraplatin
- DrugBank Accession Number
- DB04996
- Background
Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 500.283
Monoisotopic: 499.060437065 - Chemical Formula
- C10H22Cl2N2O4Pt
- Synonyms
- Satraplatin
- External IDs
- BMS-182751
- BMY-45594
- JM-216
Pharmacology
- Indication
Investigated for use/treatment in lung cancer, prostate cancer, and solid tumors.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
This drug binds to the DNA of cancer cells, inhibiting cell division.
Target Actions Organism UDNA Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Bupivacaine. - Food Interactions
- Not Available
Categories
- ATC Codes
- L01XA04 — Satraplatin
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cyclohexylamines. These are organic compounds containing a cyclohexylamine moiety, which consist of a cyclohexane ring attached to an amine group.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Cyclohexylamines
- Direct Parent
- Cyclohexylamines
- Alternative Parents
- Acetate salts / Organic transition metal salts / Organic metal halides / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Organic chloride salts / Monoalkylamines / Hydrocarbon derivatives show 1 more
- Substituents
- Acetate salt / Aliphatic homomonocyclic compound / Amine / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid salt / Cyclohexylamine / Hydrocarbon derivative / Monocarboxylic acid or derivatives show 10 more
- Molecular Framework
- Not Available
- External Descriptors
- platinum coordination entity (CHEBI:85609)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 8D7B37T28G
- CAS number
- 129580-63-8
- InChI Key
- CKNPWBAXEKSCRG-UHFFFAOYSA-J
- InChI
- InChI=1S/C6H13N.2C2H4O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6;2*1-2(3)4;;;;/h6H,1-5,7H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+4/p-4
- IUPAC Name
- platinum(4+) cyclohexanamine diacetate amine dichloride
- SMILES
- N.[Cl-].[Cl-].[Pt+4].CC([O-])=O.CC([O-])=O.NC1CCCCC1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 123974
- PubChem Substance
- 175426927
- ChemSpider
- 110493
- 1733681
- ChEBI
- 85609
- ChEMBL
- CHEMBL3833367
- Wikipedia
- Satraplatin
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 3 Completed Treatment Hormone-Refractory Prostate Cancer / Prostate Cancer 1 3 Terminated Treatment Prostate Cancer 1 2 Completed Treatment Lung Cancer 1 2 Completed Treatment Metastatic Breast Cancer 1 2 Completed Treatment Non-Small Cell Lung Cancer (NSCLC) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility 0.4 mg/ml at pH 1-7.5 Not Available - Predicted Properties
Property Value Source Water Solubility 13.5 mg/mL ALOGPS logP 1.51 ALOGPS logP 1.17 Chemaxon logS -1.4 ALOGPS pKa (Strongest Basic) 10.45 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 26.02 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 30.93 m3·mol-1 Chemaxon Polarizability 12.44 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.6502 Blood Brain Barrier + 0.7841 Caco-2 permeable - 0.6468 P-glycoprotein substrate Non-substrate 0.6858 P-glycoprotein inhibitor I Non-inhibitor 0.9881 P-glycoprotein inhibitor II Non-inhibitor 0.9863 Renal organic cation transporter Non-inhibitor 0.9154 CYP450 2C9 substrate Non-substrate 0.8261 CYP450 2D6 substrate Non-substrate 0.8462 CYP450 3A4 substrate Non-substrate 0.6351 CYP450 1A2 substrate Non-inhibitor 0.8764 CYP450 2C9 inhibitor Non-inhibitor 0.905 CYP450 2D6 inhibitor Non-inhibitor 0.9427 CYP450 2C19 inhibitor Non-inhibitor 0.866 CYP450 3A4 inhibitor Non-inhibitor 0.8794 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9813 Ames test Non AMES toxic 0.6304 Carcinogenicity Non-carcinogens 0.811 Biodegradation Ready biodegradable 0.6692 Rat acute toxicity 2.4085 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9732 hERG inhibition (predictor II) Non-inhibitor 0.9639
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
![](https://go.drugbank.com/assets/locked/DrugTargets2-682eb846d210ae4bf33ca03febccfb57bb1c61318e699b729e5df4dfab2c5b67.png)
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsDNA
Unknown
Drug created at October 21, 2007 22:23 / Updated at February 21, 2021 18:51